Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Position Decreased by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 49.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 758,405 shares of the company’s stock after selling 732,051 shares during the period. Hsbc Holdings PLC owned about 0.07% of Teva Pharmaceutical Industries worth $12,365,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TEVA. Maple Rock Capital Partners Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 68.3% in the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after purchasing an additional 1,770,000 shares during the last quarter. Glenview Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $16,752,000. Iron Triangle Partners LP boosted its holdings in shares of Teva Pharmaceutical Industries by 113.1% during the first quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares during the period. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $14,376,000. Finally, Renaissance Technologies LLC grew its position in shares of Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock worth $141,839,000 after acquiring an additional 1,031,400 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares of the company’s stock, valued at $777,285. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 1.4 %

Teva Pharmaceutical Industries stock opened at $17.51 on Monday. The firm has a market cap of $19.83 billion, a price-to-earnings ratio of -42.71, a price-to-earnings-growth ratio of 1.26 and a beta of 0.88. Teva Pharmaceutical Industries Limited has a 1 year low of $8.06 and a 1 year high of $19.08. The firm’s 50 day moving average price is $17.66 and its two-hundred day moving average price is $16.11. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. On average, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TEVA. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 10th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group raised their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Barclays boosted their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, Bank of America raised their price target on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $18.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.